Peer-influenced content. Sources you trust. No registration required. This is HCN.
ACP Hospitalist
Reframing Diagnostic Errors towards Diagnostic Excellence: The Five-step Strategy As diagnostic errors continue to pose a significant challenge in the healthcare sector, Dr. Hardeep Singh from the Baylor College of Medicine offers an innovative approach to not just reduce these errors, but to redefine and promote diagnostic excellence. By following a five-step strategy, both physicians and health organizations can enhance diagnostic procedures, ensuring higher accuracy, efficiency, and patient satisfaction. Here are the key highlights from Dr. Singh’s session at the Internal Medicine Meeting 2023:
Family Medicine/General Practice June 6th 2023
Medical Professionals Reference (MPR)
FDA Cautions Against Hidden Drug Ingredients in Joint Pain Supplements In response to recent findings, the FDA warns of significant health risks associated with three specific dietary supplements marketed for joint pain and rheumatoid arthritis relief due to the discovery of unlisted active pharmaceutical ingredients.
Anesthesiology June 6th 2023
SingleCare
Navigating the Interplay of Eliquis and Dietary Habits As physicians, understanding the nuances of apixaban (Eliquis) and its interaction with diet is crucial for optimal patient care. While taking Eliquis, there are no specific foods to avoid, but people with cardiovascular issues should steer clear of coffee and foods heavy in fat.
Cardiology June 6th 2023
Addiction Professional
Understanding Xylazine: The Rising Challenge in Opioid Crisis Management As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.
MCN: The American Journal of Maternal/Child Nursing
The article explores social interactions and institutional structures impacting the consistent practice of 24-hour rooming-in for new mothers and newborns in hospitals. Researchers employed an institutional ethnographic design, gathering data through semistructured interviews and unit observations from February 2020 to June 2021. Seven mother-baby nurses participated in interviews. Additionally, three on-unit observations lasting 2 hours each took place. From the collected data, the researchers unearthed a shared sentiment: “Baby-Friendly” practices don’t always equate to being “mother-friendly.” Three primary social interaction themes surfaced from the data analysis: viewing the mother as a patient, managing expectations, and inconsistent practices. The nurses’ perspectives revealed the complexity of managing maternal care while juggling newborn demands. Discrepancies in methods highlighted the need for standardized practices to maintain consistency across care provision. The analysis also identified three significant institutional factors that affect 24-hour rooming-in: rates of labor induction and cesarean births, nurse staffing, and nursery use monitoring. Labor induction and cesarean births often disrupt the smooth transition to rooming-in. Limited nurse staffing presents challenges in managing both mother and baby needs, while nursery use monitoring practices influence rooming-in implementation. The article’s findings provide critical insights into the daily organization and experience of 24-hour rooming-in from a […]
Hospitalist May 30th 2023
Dive into how the FDA-approved Farxiga is changing the heart failure treatment landscape. Colleagues, let’s dive into a remarkable milestone. Farxiga, known as dapagliflozin, now has FDA approval. This is groundbreaking for heart failure treatment. It applies to all patients, regardless of their left ventricular ejection fraction (LVEF) status. The approval didn’t happen overnight. Let’s talk about the DELIVER trial, a vital part of the process. It involved over 6,000 patients, all over 40. Each had heart failure, LVEF above 40%, and may or may not have had type 2 diabetes. They took either dapagliflozin or a placebo daily, plus their usual therapy. The trial had a clear goal: time to the first composite event. This included CV death, heart failure hospitalization, or an urgent heart failure visit. The goal applied to everyone, including patients with LVEF less than 60%. Fast forward about 2.3 years, the results were significant. Dapagliflozin cut the composite outcome by 18% versus the placebo. Both worsening heart failure and CV death rates dropped in the dapagliflozin group. The best part? These findings were consistent, even in patients with lower LVEF or diabetes. Expanding the picture, let’s consider two trials together: DELIVER and DAPA-HF. Over 22 […]
Cardiology May 24th 2023